Wolters Kluwer Health and New England Journal of Medicine Enter Into an Expanded Distribution Agreement

NEW YORK, Feb. 15, 2012 /PRNewswire/ -- Wolters Kluwer Health today announced it has entered into an expanded distribution agreement with the New England Journal of Medicine (NEJM), the "gold standard" for quality biomedical research and for the best practices in clinical medicine. Under the terms of the agreement, Ovid, part of Wolters Kluwer Health, will be the only medical research aggregator to distribute current, non-embargoed NEJM content to institutions and their clinicians, researchers and students who need fast access to the latest medical and clinical literature. The OvidSP medical research platform is used by more than 12,500 institutions worldwide. 

Ovid customers will have site-wide access to current issues of the New England Journal of Medicine through 1990 in PDF format, plus links to Online First articles. Ovid had previously offered NEJM content through 1993, as HTML only.

"After an extensive review of the current and future positioning of NEJM, we are pleased to be partnering with Wolters Kluwer Health," said Thomas Easley, Publisher of the New England Journal of Medicine. "The OvidSP research solution offers NEJM added global reach, allowing us to bring important medical research and clinical content to even more healthcare professionals and researchers than ever before."

"We are delighted to expand our relationship with the New England Journal of Medicine to offer our customers the most authoritative and influential medical periodical for physicians, researchers, students and healthcare professionals in the world," said Karen Abramson, President & CEO of Wolters Kluwer Health Medical Research. "We're particularly excited to make this invaluable content accessible to even more users in the global healthcare community, reaching important emerging markets to fuel research and improve clinical outcomes," said Karen Abramson, President & CEO of Wolters Kluwer Health Medical Research.

Ovid is a global information solutions provider offering clinicians, researchers, and students in the medical, scientific, and academic fields customizable solutions of content, tools, and services that make research smarter, faster, and more effective. Its flagship search platform, OvidSP is a robust search platform used by the world's leading medical and academic institutions as well as pharmaceutical companies, among other companies. The system averages more than 1.3 billion page views annually, with approximately 620 full text downloads occurring every minute, globally.

About NEJM

The New England Journal of Medicine (NEJM.org) is the world's leading medical journal and website. Founded in 1812, and owned by the Massachusetts Medical Society, NEJM publishes peer-reviewed research and interactive clinical content for physicians, educators and the global medical community.

About Wolters Kluwer Health

Wolters Kluwer Health (Philadelphia, PA) is a leading global provider of information, business intelligence and point-of-care solutions for the healthcare industry. Serving more than 150 countries and territories worldwide, Wolters Kluwer Health's customers include professionals, institutions and students in medicine, nursing, allied health and pharmacy. Major brands include traditional publishers of medical and drug reference tools, journals and textbooks, such as Lippincott Williams & Wilkins; and electronic information providers, such as Ovid®, UpToDate®, Medi-Span®, Facts & Comparisons®, Pharmacy OneSource® and ProVation® Medical.

Wolters Kluwer Health is part of Wolters Kluwer, a market-leading global information services company. Wolters Kluwer has 2010 annual revenues of 3.6 billion euros ($4.7 billion), employs approximately 19,000 people worldwide, and maintains operations in over 40 countries across Europe, North America, Asia Pacific, and Latin America.

SOURCE Wolters Kluwer Health

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.